Malignant Solid Neoplasm: Clinical Trials

6 trials for Malignant Solid Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated. 6 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Terminated 6
Phase 11Terminated 1

Follow Malignant Solid Neoplasm: new trials by email Literature Review of Malignant Solid Neoplasm trials Research Report on Malignant Solid Neoplasm

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Phase 2TerminatedM.D. Anderson Cancer Center352021-09-232026-11-17
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
Xisomab 3G3 - Lymphoma, Malignant Solid Neoplasm
Phase 2TerminatedOHSU Knight Cancer Institute92021-02-252024-01-24
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Infliximab, Intravenous Immunoglobulin Therapy, Prednisone - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 2TerminatedECOG-ACRIN Cancer Research Group12021-01-072026-09-29
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 1 / Phase 2TerminatedRoswell Park Cancer Institute42020-11-172026-01-13
Tocilizumab for Patients With Cancer and COVID-19 Disease
Tocilizumab - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 2TerminatedNational Cancer Institute (NCI)12020-05-282025-02-04
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine - Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma
Phase 2TerminatedM.D. Anderson Cancer Center162018-10-162025-04-17

Narrower conditions

Hematologic Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Lymphoma (1)  ·  Melanoma (1)  ·  Multiple Myeloma (1)  ·  Ovarian Neoplasms (1)  ·  Pneumonia (1)  ·  Respiratory Distress Syndrome (1)  ·  Ureteral Neoplasms (1)  ·  Urethral Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Broader conditions

Neoplasms (6)  ·  Neoplasms by Site (5)  ·  Hematologic Diseases (4)  ·  Hemic and Lymphatic Diseases (4)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Lung Diseases (2)  ·  Neoplasms by Histologic Type (2)  ·  Respiratory Tract Diseases (2)  ·  Urogenital Diseases (2)  ·  Urogenital Neoplasms (2)  ·  Adnexal Diseases (1)  ·  Blood Protein Disorders (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)

Interventions

Disulfides (2)  ·  Immunoglobulin G (2)  ·  tocilizumab (2)  ·  4-toluenesulfonyl fluoride (1)  ·  AB023 (1)  ·  CTLA-4 Antigen (1)  ·  Cyclophosphamide (1)  ·  Immunoglobulins (1)  ·  Immunoglobulins, Intravenous (1)  ·  Infliximab (1)  ·  Interferon alpha-2 (1)  ·  Interleukin-2 (1)  ·  Introns (1)  ·  Ipilimumab (1)  ·  Methylprednisolone (1)

Sponsors

M.D. Anderson Cancer Center (2)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  National Cancer Institute (NCI) (1)  ·  OHSU Knight Cancer Institute (1)  ·  Roswell Park Cancer Institute (1)

Countries

United States (6)

Top investigators

Amir A Jazaeri (1)  ·  Igor Puzanov (1)  ·  Jarushka Naidoo (1)  ·  Joseph Shatzel, M.D. (1)  ·  Richard F Little (1)  ·  Rodabe Amaria, MD (1)

Results publications

PMID 31401903, PMID 33568350, PMID 35537412, PMID 37328287, PMID 37970718, PMID 38309721

NIH funding

P30CA016056 (1), R01HL151367 (1), UG1CA189828 (1)